10x Genomics Preliminary Select Third Quarter Results
10x Genomics, Inc. (NASDAQ: TXG), a notable player in single cell and spatial biology, has shared its preliminary results for the third quarter recently concluded. Despite the innovative advancements in technology, the company faces challenges that have resulted in some shifts in revenue dynamics.
Quarterly Revenue Overview
Revenue Breakdown
For the latest quarter, 10x Genomics reported an expected revenue of around $151.7 million. While this figure represents only a slight 1% decline compared to the same quarter last year, it carries significant implications for the company's trajectory moving forward. The challenges faced come from various sources, impacting different revenue streams.
Instrument Revenue Insights
The revenue generated from instruments was approximately $19.1 million, indicating a steep drop of 46% from the previous year's comparable period. This revenue, which includes $7.6 million from Chromium instruments and $11.4 million from Spatial instruments, highlights the volatility in capital purchases. Customers appear to be exercising caution in their spending, which particularly affected sales of instruments this quarter.
Consumables and Services Growth
In contrast to instruments, consumables generated around $126.2 million in revenue, marking a robust 10% growth year-over-year. This includes $96.5 million from Chromium consumables and $29.7 million from Spatial consumables. Additionally, service revenue noticed a remarkable increase to about $6.4 million, showcasing a solid 48% growth compared to the previous year. Such trends point towards a demand for ongoing support and consumables that complement the initial instrument investments.
Geographical Revenue Performance
North America, EMEA, and APAC Trends
Breaking down the revenues by geography sheds light on specific regional dynamics. The Americas accounted for approximately $87.8 million in revenue, reflecting an 11% decrease from the same period last year, which illustrates the challenges faced in this crucial market. Conversely, the EMEA (Europe, the Middle East, and Africa) region reported about $37.9 million, experiencing an 18% increase, while APAC (Asia-Pacific) saw a rise in revenue to approximately $26.0 million, up by 15% year-over-year.
Cash Reserves and Financial Health
A look at the company's financial wellness shows that as of the end of the third quarter, 10x Genomics maintains a solid cash and cash equivalents balance of approximately $398 million. This strong liquidity position offers a buffer against the current challenges and provides the firm with means to invest in innovation and growth initiatives.
Management's Perspective
Serge Saxonov, Co-founder and CEO of 10x Genomics, has acknowledged that the results fell short of their expectations. He noted that recent modifications in commercial operations have led to disruptions, which particularly impacted engagement in the Americas. With customer spending being cautious, especially regarding capital equipment, revenues from instruments have felt the brunt of this shift. Despite these temporary hurdles, Saxonov remains optimistic about the company’s path forward and is confident that ongoing efforts will enhance customer engagement and drive broader adoption of the revolutionary technologies offered by 10x Genomics.
Looking Ahead: Future Financial Guidance
While these preliminary results provide a snapshot of the current situation, 10x Genomics plans to provide comprehensive guidance for the full year during their upcoming earnings call scheduled for late October. This will serve as an opportunity for stakeholders to gain deeper insights into the anticipated performance and strategic direction moving forward.
About 10x Genomics
10x Genomics is dedicated to advancing life sciences by providing innovative technology solutions that allow for deeper insights into biological systems. Their products, which range from instruments and consumables to sophisticated software, facilitate significant breakthroughs in numerous fields including oncology and neuroscience, ultimately aiming to enhance human health.
Frequently Asked Questions
What are the main highlights of the preliminary results?
The preliminary results indicate a slight decline in total revenue, significant drops in instrument sales, but notable growth in consumables and services.
How did regional performances vary in the latest quarter?
Americas saw an 11% decline, while EMEA and APAC regions experienced revenue increases of 18% and 15%, respectively.
What challenges is 10x Genomics currently facing?
The company faces challenges related to customer spending, particularly on capital purchases, leading to a decline in instrument sales.
What is the financial situation of 10x Genomics?
As of the end of the third quarter, 10x Genomics has approximately $398 million in cash reserves, providing a solid financial base for future investments.
When will 10x Genomics release its complete financial results for the quarter?
Complete financial results will be discussed during a conference call scheduled for late October.
